Evidence map›Paper›PMID 34282511›Full record

ArticleClinical rheumatology2021

Validation of the renal risk score for antineutrophil cytoplasmic antibody-associated glomerulonephritis in a Chinese population.

Xue Bai, Qiaoyan Guo, Yan Lou, Ping Nie, Yuexin Zhu, Bing Li, Ping Luo

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xue BaiDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, 130041, China.
Qiaoyan GuoDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, 130041, China.
Yan LouDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, 130041, China.
Ping NieDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, 130041, China.
Yuexin ZhuDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, 130041, China.
Bing LiDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, 130041, China. 115674160@qq.com.ORCID https://orcid.org/0000-0001-7640-9468
Ping LuoDepartment of Nephrology, The Second Hospital of Jilin University, Changchun, 130041, China. luopingjen@163.com.ORCID http://orcid.org/0000-0003-0029-0872
Second Affiliated Hospital of Jilin University · CN

Funding

Jilin Province Sanitation and Health Technology 2018J048National Natural Science Foundation of China 81970628Science and Technology Development Plan Project of Jilin province 20190304042YYScience and Technology Development Plan Project of Jilin province 20200201488JC
6 · The paper itself

Abstract

introductionIn 2018, a renal risk score of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN) based on estimated glomerular filtration rate (eGFR), normal glomeruli, and tubular atrophy/interstitial fibrosis (TA/IF) was proposed to predict renal outcomes. We aimed to evaluate this renal risk score in a myeloperoxidase (MPO)-ANCA predominant population in Northeast China.

methodsWe retrospectively analyzed the clinicopathologic data of 65 patients biopsy-proven from a Chinese medical center. Each patient was assessed by eGFR, normal glomeruli, and TA/IF, and the renal outcome was evaluated using the renal risk score.

resultsIn our study, 95.4% of patients were ANCA positive (78.5% MPO-ANCA positive and 16.9% proteinase 3-ANCA positive). The average follow-up period was 14.3 months. Thirty-four patients (52.3%) reached end-stage renal disease (ESRD). Based on the renal risk score, 8 (12.3%), 31 (47.7%), and 26 (40%) patients were divided into the low-risk, medium-risk, and high-risk groups, respectively. Kaplan-Meier survival curves revealed the high-risk group had worse renal outcomes than the low-risk group (p<0.01) and the medium-risk group (p<0.01), but the renal outcome did not differ between the low-risk and medium-risk groups (p>0.017). Similar results were obtained by the competitive survival analysis. The AUC for 3-year overall ESRD predictions was 0.845. In the regression analysis, the renal risk score was a favorable predictor for the development of ESRD (HR 3.13, 95%CI 1.58-6.19, p=0.001).

conclusionThe renal risk score is a preferred index that can predict ESRD in Chinese AAGN patients, especially in the high-risk group with worse renal outcomes. Key Points • The eGFR and percentage of normal glomeruli were valuable predictors of renal outcome, whereas TA/IF was not. • We confirmed the renal risk score is a preferred index that can predict ESRD in Chinese AAGN patients. • Based on the renal risk score, the high-risk group had worse renal outcomes than the low-risk group and the medium-risk group.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGlomerulonephritisAntibodies, Antineutrophil CytoplasmicChinaHumansRetrospective StudiesRisk FactorsAntibodies, Antineutrophil CytoplasmicANCA-associated glomerulonephritisClinicopathological manifestationOutcomeThe renal risk score

Identifiers

PMID34282511
OpenAlexW3184520692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.